Table 1.

Clinical-pathological characteristics.

	Group 1	Group 2		p-Value *
	8 (33.3%)	16 (66.7%)	TOT (%)
Gender
M	6 (75)	15 (93.75)	21 (87.5)	0.24
F	2 (25)	1 (6.25)	3 (12.5)
Age (years)
≤65	4 (50)	11 (68.75)	15 (62.5)	0.41
>65	4 (50)	5 (31.25)	9 (37.5)
Primary Site
Pancreas	0 (0)	14 (87.5)	14 (58.3)	<0.001
Ileum	5 (62.5)	1 (6.25)	6 (25)
Others	3 (37.5)	1 (6.25)	4 (16.7)
Ki67 (%)
≤2	8 (100)	1 (6.25)	9 (37.5)	<0.001
>2	0 (0)	15 (93.75)	15 (62.5)
Grading
G1	8 (100)	1 (6.25)	9 (37.5)	<0.001
G2	0 (0)	14 (87.5)	14 (58.3)
G3	0 (0)	1 (6.25)	1 (4.2)
Number ofmetastatic sites
0	0 (0)	2 (12.5)	2 (8.3)
1	2 (25)	8 (50)	10 (41.7)	0.02
2	2 (25)	4 (25)	6 (25)
3	3 (37.5)	1 (6.25)	4 (16.7)
4	1 (12.5)	1 (6.25)	2 (8.3)
Secreting
Yes	4 (50)	2 (12.5)	6 (25)	0.3
No	4 (50)	14 (87.5)	18 (75)
Association with SSA
Yes	6 (75)	14 (87.5)	4 (16.7)	0.4
No	2 (25)	2(12.5)	20 (83.3)
Number of previous therapies
0	0 (0)	3 (18.7)	3 (12.5)
1	0 (0)	4 (25)	4 (16.7)
2	4 (50)	1 (6.25)	5 (20.8)
3	3 (37.5)	5 (31.25)	8 (33.3)	0.11
4	0 (0)	2 (12.5)	2 (8.3)
5	0 (0)	1 (6.25)	1 (4.2)
6	0 (0)	0 (0)	0 (0)
7	1 (12.5)	0 (0)	1 (4.2)
Best objective response **
Partial response	1 (16.7)	2 (12.5)	3 (13.6)	0.75
Stable disease	4 (66.7)	13 (81.25)	17 (77.3)
Disease progression	1 (16.7)	1 (6.25)	2 (9.1)
Number of subsequent therapies ***
0	2 (28.6)	3 (18.75)	5 (21.7)
1	5 (71.4)	3 (18.75)	8 (34.8)
2	0 (0)	3 (18.75)	3 (13)	0.14
3	0 (0)	3 (18.75)	3 (13)
4	0 (0)	3 (18.75)	3 (13)
5	0 (0)	1 (6.25)	1 (4.4)
Primary removal
Yes	7 (87.5)	6 (37.5)	13 (54.2)	0.03
No	1 (12.5)	10 (62.5)	11 (45.8)

(* Fisher’s exact test, statistical significance at a level of p < 0.05; ** evaluable in only 22 patients; *** evaluable only in 23 patients).